AI-generated summary
The authors report a randomized, double-blind trial of 8% arginine toothpaste and photobiomodulation, alone or combined, for dentin hypersensitivity in 60 enrolled participants, 54 of whom completed the study. All four groups improved over 8 weeks, but the authors found no statistically significant differences between interventions and no additive effect from combining them.
- Participants
- 60
- Who or what was studied
- Adults with dentin hypersensitivity
- Limits stated in the abstract
- The abstract does not report the population's age or other characteristics, and it reports no control for the improvement seen across all groups.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
Purpose
To evaluate the efficacy of 8% arginine-based desensitizing toothpaste and photobiomodulation (PBM), used alone or in combination, in the treatment of dentin hypersensitivity (DH).
Materials And Methods
This randomized, double-blind, parallel-group clinical trial included participants with DH who were allocated into four groups: laser group (LG), arginine group (AG), combined laser and arginine group (LAG), and control group (CG). Clinical assessments were performed at baseline and after 2, 4, and 8 weeks. DH was evaluated using evaporative (air stimulus) and tactile tests applied to the cervical-buccal surface of the teeth, with pain intensity recorded using the Visual Analog Scale (VAS). Linear mixed-effects models were used for longitudinal continuous outcomes (Schiff and VAS scores), while generalized estimating equations were applied for tactile sensitivity outcomes, adopting a significance level of 5%.
Results
A total of 60 participants were enrolled, and 54 completed the study. A significant reduction in DH was observed over time for both Schiff scores and VAS values (p < 0.001). Mean Schiff scores decreased from 5.0 (± 0.8) at baseline to 1.9 (± 1.3) at 8 weeks, while VAS scores also showed significant reductions. All groups demonstrated improvement in DH symptoms; however, no statistically significant differences were observed between interventions at any time point (p > 0.05).
Conclusions
All evaluated therapies were effective in reducing DH over the 8-week follow-up period, with a progressive reduction in symptoms over time. However, no statistically significant differences were observed between the interventions, and no additive effect was identified for the combined therapy. CLINICAL
Trial Registration
Brazilian Clinical Trials Registry ReBEC; RBR2vxzvkz, October 13th, 2023.
Abstract reproduced under the CC BY license. Source: PubMed, a service of the National Library of Medicine.
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Laser, Low-level laser therapy, Visual analogue scale, Photobiomodulation, Trial registration, Control group. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.